Results 201 to 210 of about 101,164 (260)
αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. [PDF]
Cobb DA +10 more
europepmc +1 more source
Spatiotemporal Targeting Randle Cycle and Immune Checkpoint for Potent Antitumor Therapy
A glucose oxidase‐based nanogel (GOX‐NG) system using catechol‐functionalized alginate, exhibits enhanced tumor penetration, prolonged retention, and sustained glucose depletion in the tumor microenvironment. When combined with a fatty acid oxidation inhibitor, it implements dual metabolic suppression, thereby enhancing ROS‐induced immunogenic cell ...
Yuan Gao +11 more
wiley +1 more source
<i>BRCA2</i> Reversion Mutation after Neoadjuvant Dose-Dense EC and Dose-Dense Paclitaxel in Triple-Negative Breast Cancer: A Case Report and Literature Review. [PDF]
Hikino H, Otani A, Makino Y.
europepmc +1 more source
SPADE integrates spatial transcriptomics with single‐cell RNA sequencing by using cell–cell communications (CCC) as a guide for spatial mapping. It improves cell‐type localization, enhances sparse gene‐expression signals, and reveals CCC programs at single‐spot resolution.
Xinyi Li, Ning Zhang, Zijie Jin
wiley +1 more source
Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort. [PDF]
Narasimhan RM +7 more
europepmc +1 more source
Inhibition of KDELR2 in a small fraction of tumor cells generates sustainable immunogenic cell death conditions within the tumor microenvironment. These conditions promote the regression of tumors in a T cell independent manner. During regression, macrophages prime T cells that subsequently provide systemic protection against recurrence. The potency of
Shakti P Pattanayak +6 more
wiley +1 more source
Microglandular adenosis, triple negative breast carcinoma and DNA repair defects. [PDF]
Bedell M +12 more
europepmc +1 more source
A fully synthetic four‐component vaccine has been developed combining Tn antigen, vizantin (Mincle agonist), rhamnose (antibody recruitment), and mannose (CD206 targeting). By synergistically activating Mincle, FcγR, and CD206 pathways, it elicits strong IgG switching and cytotoxic T‐cells, significantly inhibiting tumors in mice.
Wenbo Ming +9 more
wiley +1 more source

